Sanofi Files 6-K with December Press Releases
Ticker: SNYNF · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, financial-update
TL;DR
Sanofi dropped a 6-K with new press releases – check P&L ex-Opella and rilzabrutinib ASH data.
AI Summary
On December 13, 2024, Sanofi filed a Form 6-K with the SEC, incorporating by reference four press releases published in December 2024. These exhibits include information on the profit and loss of Sanofi excluding Opella, and details regarding rilzabrutinib at the ASH conference.
Why It Matters
This filing provides investors with updated financial and operational information from Sanofi, including specific details on business segment performance and clinical trial updates.
Risk Assessment
Risk Level: low — This is a routine filing providing information already disseminated through press releases, with no new material financial events or strategic shifts announced.
Key Players & Entities
- Sanofi (company) — Registrant
- Opella (company) — Business segment excluded from profit and loss information
- rilzabrutinib (drug) — Subject of press release regarding ASH conference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information that Sanofi has made or is required to make public in France or to its security holders, specifically incorporating by reference four press releases published in December 2024.
Which specific press releases are incorporated into this filing?
The filing incorporates Exhibits 99.1, 99.2, 99.3, and 99.4, which include information on the profit and loss of Sanofi excluding Opella and details about rilzabrutinib at the ASH conference.
Does Sanofi file annual reports under Form 20-F or Form 40-F?
Sanofi indicates that it files annual reports under Form 20-F.
What is Sanofi's principal executive office address?
Sanofi's principal executive offices are located at 46, avenue de la Grande Armée, 75017 Paris, France.
What is the SIC code for Sanofi?
Sanofi's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-12-13 11:07:45
Filing Documents
- d913939d6k.htm (6-K) — 10KB
- d913939dex991.htm (EX-99.1) — 13KB
- d913939dex992.htm (EX-99.2) — 38KB
- d913939dex993.htm (EX-99.3) — 42KB
- d913939dex994.htm (EX-99.4) — 19KB
- g913939g05k61.jpg (GRAPHIC) — 1KB
- g913939g1213103418819.jpg (GRAPHIC) — 3KB
- g913939g1213103419632.jpg (GRAPHIC) — 3KB
- g913939g27p67.jpg (GRAPHIC) — 1KB
- g913939g99b84.jpg (GRAPHIC) — 1KB
- 0001193125-24-278124.txt ( ) — 135KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 13, 2024 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3